Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma
Neuroblastoma, Sarcoma
About this trial
This is an interventional treatment trial for Neuroblastoma focused on measuring recurrent neuroblastoma, recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor
Eligibility Criteria
DISEASE CHARACTERISTICS: Diagnosis of Ewing's sarcoma OR neuroblastoma Relapsed or refractory disease Epstein-Barr virus positive PATIENT CHARACTERISTICS: Age 1 to 30 Performance status Lansky 70-100% OR ECOG 0-2 Life expectancy At least 8 weeks Hepatic Bilirubin < 2.0 mg/dL AST and ALT < 2.5 times normal (in the absence of liver metastases) Patients without evidence of an obvious relationship between AST/ALT and disease activity are not eligible Hepatitis B antigen and core antibody negative Hepatitis C antibody negative Renal Creatinine clearance > 50 mL/min Immunologic HIV 1 and 2 negative HTLV 1 and 2 negative Other Not pregnant Negative pregnancy test Fertile patients must use effective contraception No other moribund condition PRIOR CONCURRENT THERAPY: Biologic therapy At least 3 months since prior autologous stem cell transplantation Chemotherapy Not specified Endocrine therapy Not specified Radiotherapy Not specified Surgery Not specified
Sites / Locations
- Penn State Cancer Institute at Milton S. Hershey Medical Center